Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials

Supplemental Data

Table A1.

Description of NABTT CNS Consortium Trials Included in This Study

NABTT Trial	Phase	No. of Patients	Description of Treatment
9-Aminocamptothecin	I/II	22/21	Administered as a 72-hour IV infusion every 2 weeks; starting dose of 850 μg/m^2/24 hours was escalated to 1,611 μg/m^2/24 hours for patients taking EIACs
Suramin	II	11	Fixed doses infused during 1 hour
Oral phenylbutyrate	I	21	Dose escalations of 9, 18, 27, and 36 g/d administered orally in three equally divided doses
Aprinocarsen	II	21	Administered as a 21-day infusion at a rate of 2.0 mg/kg/d, followed by 7 days of no treatment, then repeated
Irinotecan	I/II	40/18	Weekly 90-minute IV infusion for 4 weeks, then repeated every 6 weeks; starting dose was 125 mg/m^2/wk, MTD was 117 mg/m^2/wk for EIAC-and 411 mg/m^2/wk for patients taking EIACs
Oral procarbazine	I	49	Dose escalation of procarbazine given orally once daily for 5 consecutive days repeated monthly; starting dose was 200 mg/m^2/d and MTD was 393 mg/m^2/d for patients taking EIACs and ≥ 334 mg/m^2/d for patients not taking EIACs
Carmustine wafers	I	43	Dose escalation study of carmustine polymers from 6.5% to 28% carmustine by weight; MTD was 20%

NABTT Trial	Phase	No. of Patients	Description of Treatment
GliaSite RTS	I	21	Safety and feasibility study of an implanted inflatable balloon catheter and liquid iodine-125 brachytherapy
Onyx-015	I	24	Dose escalation study of an intratumoral injection with an E1B-attenuated adenovirus
Carmustine and IV O^6-BG	I	42	Establish the dose of continuous IV infusion of O^6-BG (combined with 3.85% carmustine wafers) that suppresses alkylating-DNA alkyl transferase and escalate duration of infusion

Abbreviations: NABTT, New Approaches to Brain Tumor Therapy; IV, intravenous; EIAC, enzyme-inducing anticonvulsants; MTD, maximum-tolerated dose; RTS, Radiation Therapy System; O^6-BG,O^6-benzylguanine.